SCHEDULE 13G: Nantahala Capital Management Discloses 8.63% Stake in Anebulo Pharmaceuticals

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 8.63% in Anebulo Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, an investment adviser, along with its managing members Wilmot B. Harkey and Daniel Mack, collectively reported beneficial ownership of 3,547,398 shares of Anebulo Pharmaceuticals, Inc. Common Stock.
• This aggregate amount represents 8.63% of the total outstanding shares of Anebulo Pharmaceuticals, Inc. as of December 31, 2024.
• The reported shares include 511,073 shares that can be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• The Reporting Persons hold shared voting power and shared dispositive power over all 3,547,398 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, has the right to receive dividends or proceeds from the sale of more than five percent of the outstanding common stock beneficially owned by Nantahala.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational news, but rather a regulatory filing of a significant stake.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive investment stake in a publicly traded pharmaceutical company. It indicates that a notable investment firm and its principals view Anebulo Pharmaceuticals as a viable investment, without signaling an intent to influence corporate control.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment firm can be viewed positively as a vote of confidence, potentially influencing market perception and liquidity. It also identifies a major shareholder.

Key Dates

Keywords

Anebulo Pharmaceuticals, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Shareholding, Warrants